Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

PTIX

Protagenic Therapeutics Inc

Nov 26 • 04:00PM ET

2.23

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: ACAD AXSM BTAI SAGE CORT ITCI VNDA NERV SCPH VKTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.76	Insider Own	4.47%	Shs Outstand	1.85M	Perf Week	10.40%
Market Cap	4.30M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.84M	Perf Month	-19.20%
Enterprise Value	4.21M	PEG	-	EPS next Q	-	Inst Own	4.30%	Short Float	3.10%	Perf Quarter	-37.18%
Income	-8.86M	P/S	-	EPS this Y	-	Inst Trans	6.80%	Short Ratio	0.55	Perf Half Y	-41.47%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-195.41%	Short Interest	0.06M	Perf YTD	-67.49%
Book/sh	-2.15	P/C	1.05	EPS next 5Y	-	ROE	-512.79%	52W High	14.28 -84.38%	Perf Year	-75.49%
Cash/sh	2.13	P/FCF	-	EPS past 3/5Y	2.78% -10.56%	ROIC	-	52W Low	1.83 21.86%	Perf 3Y	-93.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.59% 9.26%	Perf 5Y	-99.85%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	42.32%	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.41	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.60	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.41	EPS Q/Q	73.01%	SMA20	4.33%	Beta	1.08	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-23.60%	Rel Volume	0.64	Prev Close	2.23
Employees	3	LT Debt/Eq	-	Earnings	-	SMA200	-35.42%	Avg Volume	103.90K	Price	2.23
IPO	Dec 18, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	66,820	Change	0.00%

Nov-13-25 08:22AM	Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study (ACCESSWIRE) +9.38%
Aug-22-25 05:25PM	Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance (ACCESSWIRE) +6.37%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +86.84%
08:12AM	Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders (ACCESSWIRE)
Jul-30-25 08:30AM	Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates (GlobeNewswire)
02:40PM	Loading…
May-29-25 02:40PM	Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy (Insider Monkey)
May-21-25 09:15AM	Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity (ACCESSWIRE) -10.76%
May-19-25 07:43AM	Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders (ACCESSWIRE) +266.34%
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Apr-29-25 04:00PM	Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split (ACCESSWIRE)
Nov-05-24 08:12AM	Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-29-24 10:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESS Newswire) +13.73%
Jun-25-24 06:53AM	PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024 (InvestorPlace) +8.46%
May-22-24 08:12AM	Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders (ACCESSWIRE) +12.60%
May-01-24 08:38AM	Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial (ACCESSWIRE) -5.58%
08:42AM	Loading…
Apr-17-24 08:42AM	Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit (ACCESSWIRE)
Apr-01-24 09:53PM	PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:20PM	Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results (ACCESSWIRE)
Mar-27-24 08:42AM	Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders (ACCESSWIRE)
Mar-25-24 05:00PM	Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call (ACCESSWIRE) +12.37%
Mar-21-24 08:41AM	Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice (ACCESSWIRE) +5.93%
Feb-13-24 08:30AM	Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders (ACCESSWIRE)
Dec-12-23 07:30AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE) +15.65%
Oct-13-23 09:00AM	Protagenic Therapeutics Announces Date of Annual Shareholder Meeting (ACCESSWIRE) +13.49%
Sep-26-23 08:18AM	Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 (ACCESSWIRE)
Mar-22-23 12:55PM	Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split (ACCESSWIRE) +20.97%
Apr-26-22 08:15AM	Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th (ACCESSWIRE) -5.75%
Nov-16-21 09:58AM	Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update (GlobeNewswire)
Aug-30-21 09:15AM	Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET (GlobeNewswire)
Aug-17-21 07:45AM	Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update (GlobeNewswire)
04:21PM	Loading…
Jul-23-21 04:21PM	Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial (GlobeNewswire) -9.35%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +8.75%
Jul-06-21 06:17AM	Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET (GlobeNewswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +10.47%
Jun-16-21 09:15AM	Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th (GlobeNewswire)
Apr-29-21 03:06PM	Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq (GlobeNewswire) +5.36%
Apr-26-21 08:58PM	Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering (GlobeNewswire) -24.29% -39.62%
Dec-16-20 09:15AM	Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial (GlobeNewswire)
Sep-08-20 12:10PM	Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing (GlobeNewswire)

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

PTIX

Protagenic Therapeutics Inc

Upgrade your FINVIZ experience